D. E. Shaw & Co. Inc. Sells 387,055 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

D. E. Shaw & Co. Inc. reduced its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 68.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 180,676 shares of the company's stock after selling 387,055 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.21% of IDEAYA Biosciences worth $4,643,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. R Squared Ltd acquired a new position in IDEAYA Biosciences in the fourth quarter valued at about $35,000. Daiwa Securities Group Inc. boosted its holdings in shares of IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after acquiring an additional 853 shares in the last quarter. KBC Group NV grew its position in IDEAYA Biosciences by 84.6% during the 4th quarter. KBC Group NV now owns 4,197 shares of the company's stock worth $108,000 after acquiring an additional 1,923 shares during the last quarter. Cibc World Markets Corp acquired a new stake in IDEAYA Biosciences during the 4th quarter valued at $203,000. Finally, Mariner LLC boosted its stake in IDEAYA Biosciences by 9.8% in the fourth quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after purchasing an additional 869 shares in the last quarter. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Trading Down 2.4%

Shares of NASDAQ:IDYA traded down $0.48 during trading on Wednesday, hitting $19.15. 1,597,774 shares of the company's stock were exchanged, compared to its average volume of 1,008,265. The firm has a market cap of $1.68 billion, a P/E ratio of -5.80 and a beta of 0.26. The firm has a 50-day moving average price of $17.64 and a two-hundred day moving average price of $22.09. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the business earned ($0.53) EPS. As a group, research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analysts Set New Price Targets

Separately, Stephens reiterated an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $54.27.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.